Controversial gene-editing procedure to fight AIDS is again being considered by scientists, despite disastrous results a decade ago


When the Centers for Disease Control and Prevention announced last year that people who take HIV medication religiously for six months can theoretically get to point where they can’t transmit the virus, it was considered a huge advancement. There remains no cure for HIV and AIDS, although it is not the death sentence that it used to be. There have been triumphs and setbacks in the quest to find a cure, and now scientists are considering revisiting a past disaster in hopes of emerging victorious this time around.

A controversial gene editing procedure is at the heart of the new approach. Gene editing recently gained FDA approval for treating cancer and one type of blindness, and some researchers are hoping that HIV/AIDS can soon be added to the list.

Gene therapy has already helped some patients make their cells more resistant to HIV. In 2014, scientists removed some of Matt Chappell’s blood cells, disabled a gene in order to help the cells resist the HIV virus, and then returned the edited cells to his body. It has been the closest thing to a cure for Chappell, who has gone from taking the strongest AIDS drugs available for more than a decade to not needing the medications at all for more than three years. His body even managed to keep the virus in check in the midst of cancer treatments that wreaked havoc on his immune system last year.

Chappell’s story is far from ordinary. Of the 100 people who took part in those experiments, just a few of them were able to give up their HIV drugs in the long run. The rest of them still have to take medication to suppress their HIV.

Despite these discouraging numbers, the researchers want to give it another try. They believe that they can improve this treatment and are now testing some tweaked approaches in which they’ve doctored DNA in a different way.

Temple University researchers have developed a method of gene editing that can detect HIV DNA in a person’s T-cell genome, which is a set of DNA pertaining to a certain kind of white blood cells. When this DNA has been edited out, the loose genome ends that were previously attached to the HIV will be rejoined by the DNA repair system within the cell. This leaves the cell free from HIV and protected from new infections.

An Incarcerated Individual With Weight Loss and Interstitial Pulmonary Infiltrates


Case

A 60-year-old man incarcerated in Ohio presented to the emergency department after a syncopal episode. He reported recent exposure to COVID-19 but had no fevers, chest pain, cough, dyspnea, or diarrhea. He had unintentionally lost 13.6 kg over 2 years. His temperature was 37 °C (98.5 °F); blood pressure, 124/75 mm Hg; pulse, 123/min; respiratory rate, 22/min; and oxygen saturation, 96% on room air. Findings on physical examination were unremarkable. His white blood cell count was 3300/μL (reference, 4500-11 000/μL) with an absolute lymphocyte count of 200/μL (reference, 1000-4800/μL). Chest radiograph showed bilateral reticulonodular opacities. He was hospitalized and treated with azithromycin, remdesivir, and dexamethasone despite 3 negative SARS-CoV-2 polymerase chain reaction (PCR) test results. Two days after hospital discharge, he presented to the emergency department with recurrent syncope. His temperature was 38.1 °C (100.6 °F); blood pressure, 122/82 mm Hg; pulse, 135/min; and oxygen saturation, 86% on room air. A computed tomography scan revealed diffuse bilateral pulmonary micronodular opacities, a 2.2-cm nodule in the lingula, and mediastinal and hilar lymphadenopathy (Figure 1). Results of HIV testing were positive for HIV-1 antibodies.

Patient’s computed tomography pulmonary angiogram.

Patient’s computed tomography pulmonary angiogram.

What Would You Do Next?

  1. Check urine and serum Histoplasma antigen test results
  2. Order a positron emission tomography scan
  3. Perform bronchoscopy with transbronchial biopsy
  4. Treat with 7 days of intravenous cefepime and vancomycin

Discussion

Diagnosis

Disseminated histoplasmosis

What to Do Next

A. Check urine and serum Histoplasma antigen test results

Discussion

The key to the correct diagnosis is recognizing that hypoxemia and diffuse micronodular pulmonary opacities in a patient with HIV is characteristic of disseminated histoplasmosis. A positron emission tomography scan (choice B) is not recommended because it will not provide a definitive diagnosis. Less invasive testing should be pursued prior to bronchoscopy and transbronchial biopsy (choice C). The imaging findings were inconsistent with bacterial pneumonia, so intravenous antibiotics (choice D) are not indicated.

Histoplasma capsulatum is a soil-based fungus associated with bird and bat droppings.1 Exposure occurs via inhalation of fungal spores.1 While endemic in the Ohio and Mississippi River valleys, all US continental states have documented cases of histoplasmosis.2 H capsulatum is endemic in Central and South America, sub-Saharan Africa, and South/Southeast Asia.3 Most patients with acute pulmonary histoplasmosis are asymptomatic or have mild, self-limited cough and remain undiagnosed.4 However, severe pneumonia can occur, especially in patients with immunosuppression or who inhale a large quantity of spores.4 Infants and adults older than 55 years are at higher risk of severe histoplasmosis. Risk factors for dissemination include HIV with CD4 cell count less than 150/mm3, immunosuppressive medications (eg, corticosteroids, tumor necrosis factor inhibitors), hematologic malignancies, and solid organ transplantation.4 Patients with disseminated histoplasmosis typically have fever, fatigue, weight loss, and shortness of breath, and may also have diarrhea, headaches, altered mental status, and rash.5,6 Common laboratory findings include anemia, thrombocytopenia, leukopenia, and elevated liver enzyme and lactodehydrogenase levels.5 The differential diagnosis of disseminated histoplasmosis includes tuberculosis, cryptococcus, coccidioidomycosis, blastomycosis, malignancy, and sarcoidosis.5,6

To diagnose disseminated histoplasmosis, serum and urine tests for Histoplasma antigen are the tests of choice and have sensitivities of 95% and specificities of 97%.7 Disseminated histoplasmosis is fatal if untreated.5 Mild to moderate disseminated histoplasmosis is treated with 200 mg of oral itraconazole 3 times daily, followed by twice-daily dosing for 12 months.7,8 For severe disseminated histoplasmosis (eg, respiratory, circulatory, or kidney failure; neurologic signs; coagulation abnormalities; or symptoms that limit self-care), induction therapy consists of intravenous liposomal amphotericin B for 2 weeks, or for 4 to 6 weeks if there is central nervous system (CNS) involvement.7,8 Recommended maintenance therapy is oral itraconazole for 12 months to lifelong, depending on risk of reinfection or relapse, which occurs most commonly in patients with CNS disease.7,8 Mortality rates in patients with HIV and disseminated histoplasmosis range from 10% to 60%, depending on access to care.9

Patient Outcome

The patient’s urine Histoplasma antigen level was greater than 25 ng/mL and serum Histoplasma antigen level was greater than 20.0 ng/mL (reference positive, >0.20 ng/mL for both). Serum testing revealed negative T-spot, negative Cryptococcus antigen, and negative Coccidioides antibody findings. Results of Mycobacterium tuberculosis PCR and Pneumocystis jirovecii pneumonia PCR of bronchoalveolar lavage (BAL) fluid were negative. Results of brain magnetic resonance imaging were normal. Cerebrospinal fluid cell count, differential, total protein level, and glucose level were normal. HIV viral load was 3.9 million copies/mL, and CD4 cell count was 15/mm3. The patient was treated with 3 days of oral itraconazole (200 mg 3 times daily), followed by twice-daily dosing. Antiretroviral treatment (ART) with bictegravir-emtricitabine-tenofovir alafenamide was started on hospital day 10. On discharge, results of fungal, blood, BAL, and acid-fast bacillus cultures and cerebrospinal fluid Histoplasma antigen testing were pending. He was to continue ART, itraconazole (200 mg twice daily), and trimethoprim-sulfamethoxazole (160-800 mg 3 times per week) for P jirovecii pneumonia prophylaxis.

Twenty days later, the patient was readmitted to the hospital with headaches. Results of prior fungal blood and BAL cultures and CNS Histoplasma antigen testing were positive but had not been reported. He received treatment for CNS histoplasmosis with intravenous liposomal amphotericin B (3 mg/kg/d) for 6 weeks. Bronchoscopy with transbronchial biopsy, performed to evaluate the pulmonary nodule, showed necrotizing granulomas with yeast (Figure 2). After a 44-day hospitalization, the patient was discharged taking ART, itraconazole (200 mg 3 times daily), and trimethoprim-sulfamethoxazole. In clinic 18 months later, he was asymptomatic, with a CD4 count of 182/mm3 and HIV viral load of 100 copies/mL. All of his prior medications were continued, including itraconazole (200 mg twice daily) due to the high risk of reinfection or relapse associated with disseminated histoplasmosis involving the CNS, especially with CD4 cell count less than 200 cells/mm3.

Transbronchial biopsy pathology (Gomori methenamine silver stain, original magnification x40).

Transbronchial biopsy pathology

Mono: A Hidden Culprit in Chronic Illness


Epstein Barr disease stretches further than the infectious mononucleosis—with frequently overlooked influence on chronic diseases such as multiple sclerosis.

Tanya Francis, 45, couldn’t have predicted that a virus she encountered at 14 would drastically affect her health years later. Diagnosed with mononucleosis, a common adolescent ailment caused by the Epstein-Barr virus (EBV), Ms. Francis’s experience deviated from the norm. Rather than being a fleeting teenage illness, EBV marked the beginning of a long-term battle.

Ms. Francis’ ensuing struggle with fatigue, joint pain, vertigo, and a 2018 multiple sclerosis diagnosis reflects a wider narrative. Her experience sheds light on EBV’s complex and frequently overlooked influence on chronic diseases.

​​Unveiling the Epstein-Barr Virus

The Epstein-Barr virus, less familiar to many than the common cold but arguably as widespread, is stepping into the spotlight of medical research, revealing its complex role in numerous health issues.

While best known for causing infectious mononucleosis, often called the “kissing disease,” the influence of EBV stretches much further. “EBV is one of the most common human viruses,” explains Dr. Jeffrey Dunn, a neurologist at Stanford Medicine focusing on immune-mediated neurological diseases. “If you checked everybody for whether they’ve been exposed to Epstein Barr virus, 95 percent plus will have it.”

As a member of the herpesvirus family, EBV is a double-stranded DNA virus capable of remaining latent in the body. “Much like herpes simplex virus, once you’re infected with EBV, you can never eradicate it,” Paul Gisbert Auwaerter, M.D. and professor at Johns Hopkins University School of Medicine, told The Epoch Times. He emphasizes that this ability to lie dormant is central to the virus’s nature, allowing it to stay hidden for prolonged periods.

EBV is commonly passed through oral secretions, often in simple acts like sharing drinks or kissing. However, its transmission extends to blood transfusions, organ transplants, and breast milk. The presence of EBV in genital secretions further underscores its capacity to spread via multiple bodily fluids.

EBV infection typically occurs in childhood or adolescence, frequently producing mild or unnoticeable symptoms. In teens or young adults, it often manifests as infectious mononucleosis, marked by fever, sore throat, and swollen glands. But the true concern lies in what unfolds long after these initial symptoms subside.

A Spectrum of Linked Diseases

Beyond its role in causing mononucleosis, the Epstein-Barr virus is now recognized as a key player in various autoimmune and inflammatory diseases. What was once speculative is now backed by growing scientific evidence.

A pivotal study tracking over 10 million U.S. military recruits for two decades revealed a startling connection between EBV and multiple sclerosis (MS). The research found a 32-fold increase in MS risk post-EBV infection, shedding light on the virus’s possible role in autoimmune diseases.

Alberto Ascherio, M.D., Harvard epidemiologist and senior author, reflected on the study in a press release. “This is a big step because it suggests that most MS cases could be prevented by stopping EBV infection, and that targeting EBV could lead to the discovery of a cure for MS.”

While the exact mechanisms by which EBV may lead to MS are still under investigation, a 2022 Stanford study may offer a clue. The research highlighted a unique aspect of EBV’s interaction with MS. The virus contains elements mimicking brain and spinal cord proteins, leading the immune system to mistakenly attack the body’s nerve cells, a phenomenon termed “molecular mimicry.”

Beyond MS, EBV is linked to other autoimmune diseases such as lupus, Type 1 diabetes, and rheumatoid arthritis. These findings suggest that EBV’s role extends beyond dormancy, potentially triggering various autoimmune responses.

Research is also probing potential connections between EBV and gastrointestinal disorders, including irritable bowel syndrome and celiac disease.

In cancer research, EBV’s influence is notably significant. It contributes to cancers like Burkitt’s lymphoma, Hodgkin’s lymphoma, gastric cancer, and nasopharyngeal carcinoma. Dr. Dunn highlights, “It’s been estimated that there may be 200,000 cancer cases per year associated with EBV,” a number that becomes meaningful when considering public health and potential treatments, he explains.

“We’re dealing with a virus that has the capability to affect the body in multiple ways,” explains Dr. Auwaerter. He emphasizes, however, that while there’s a noticeable link between EBV and certain autoimmune diseases, the exact ways EBV influences these conditions remain to be fully understood by researchers.

The Immune System’s Role in EBV Activation

The Epstein-Barr virus is not just widespread—its true danger lies in its ability to manipulate the human immune system. Its threat often becomes pronounced when our natural defenses are weakened.

“It’s a delicate balance,“ Dr. Michael Bauerschmidt, chief medical officer at Deeper Healing Wellness Center, told The Epoch Times. ”The virus itself can remain harmless for years, but under certain conditions, it can become a formidable adversary.”

A key element is the immune response to EBV. Usually, a robust immune system keeps the virus in check. However, if the immune system is compromised due to stress, illness, or other factors, EBV may reactivate.

“The diagnosis is not the disease,” states Dr. Bauerschmidt. “Yes, EBV causes problems, but only because the individual immune system is unable to keep it contained.”

Factors weakening the immune system and possibly reactivating EBV are numerous. “It’s about everything,” Dr. Bauerschmidt explains, emphasizing lifestyle influences, particularly nutrition. A nutrient-deficient diet can weaken immune defenses, allowing EBV reactivation. Conversely, a nutrient-rich diet might strengthen the immune response against EBV.

Environmental elements also play a role. Dr. Bauerschmidt points to exposure to mold, heavy metals, pesticides, and electric and magnetic fields as factors that can weaken the immune system. “These environmental factors can create a perfect storm for EBV reactivation,” says Dr. Bauerschmidt.

Dr. Bauerschmidt asserts that the approach to understanding and managing EBV must be holistic. “Focusing solely on the virus is insufficient. We must consider the body’s entire ecosystem.” He advocates for a strong, balanced immune system as the primary defense.

Ben Galyardt, chiropractor and founder and CEO of F8 Well Centers, aligns with this view, particularly considering recent findings on Long COVID and EBV reactivation. A 2023 study showed higher EBV reactivation rates in COVID-19 patients. “A range of physical stressors can provoke EBV reactivation, initiating an inflammatory response within the body,” he notes.

Dr. Auwaerter, however, questions the effectiveness of merely boosting the immune system against EBV-linked conditions. Acknowledging the benefits of a healthy lifestyle, he cautions, “There’s no definitive proof that less immune activation or reactivation leads to less disease.”

He points out the complexity, especially with autoimmune conditions, where stimulating the immune system might be counterproductive. “The critical question is whether the issues stem directly from the virus or from the immune response,” he adds, underlining the intricacies of EBV-related health challenges.

Navigating the Challenges of Diagnosis

Diagnosing conditions associated with EBV is a complex task in medicine, largely due to the virus’s prevalence and dormant nature. A significant issue is that standard EBV tests often fail to provide clear insights into the virus’s active role in current health issues.

EBV testing typically involves checking for antibodies against specific EBV antigens to assess recent or past infections. According to the Centers for Disease Control (CDC), anti-VCA IgM appears early in an EBV infection and usually vanishes within four to six weeks, signifying a recent infection. On the other hand, anti-VCA IgG emerges in the acute phase, peaks at two to four weeks post-onset, and then remains for life, indicating past exposure. The simultaneous presence of VCA and EBNA antibodies generally suggests past infection, a common finding in adults.

However, Mr. Galyardt points out the limitations of these tests. “Since most adults have encountered EBV, standard tests like anti-VCA IgG, IgM, or EBNA offer limited information about ongoing health issues.” Although these tests can identify past exposure or acute infections, they don’t conclusively show whether EBV is currently affecting a patient’s health.

Mr. Galyardt suggests a more comprehensive diagnostic method, focusing on white blood cell counts. “A low white blood cell count coupled with a high lymphocyte percentage often indicates chronic viral infection, irrespective of EBV test results.” This approach considers the body’s overall state, not just specific EBV markers.

Interpreting EBV antibody tests requires considering the patient’s symptoms and medical history. The connection between EBV and various chronic conditions, like autoimmune diseases or cancers, isn’t widely acknowledged in general practice, potentially leading to diagnostic and treatment oversights.

While EBV testing can be instrumental in diagnosing conditions like infectious mononucleosis or chronic active Epstein-Barr Virus (CAEBV), Dr. Auwaerter recommends a cautious approach when it comes to testing for other issues, such as chronic fatigue, Long COVID, MS, lupus, or lymphoma. “In my opinion, there’s no benefit,” he remarks, highlighting that the scientific community is still working to fully understand how EBV is connected to various health conditions.

EBV Treatment: Searching for Effective Strategies

Current medical understanding acknowledges the absence of a specific treatment or cure for EBV, as per the CDC. Although no vaccine is yet available, the National Institutes of Health began a clinical trial for an EBV vaccine in 2022.

This lack of a targeted cure has led to diverse treatment approaches. Health care providers often use antiviral treatments like acyclovir, but these have shown limited effectiveness against EBV’s latent presence in cells.

Catherine Bollard, M.D., and Jeffrey Cohen, M.D., note in a paper, “Once EBV infection is established, acyclovir has no effect on virus-infected T cells in T-cell CAEBV.” Echoing this, Mr. Galyardt adds, “There’s no great antiviral. COVID proved that,” highlighting the limitations of current treatments.

Other treatments like interferons and immunoglobulin therapy have shown inconsistent results, and while immune cell therapy is promising in post-transplant EBV cases, stem cell transplants have had varied success. This underlines the ongoing challenge of finding effective EBV treatments.

Mr. Galyardt advocates a proactive health approach, emphasizing the importance of strengthening the body’s defenses against viruses like EBV. “The vast majority of people carry some form of chronic viral load, but it’s not inevitable for it to become problematic,” he says. His recommendations for keeping EBV inactive include adequate sleep, adrenal function maintenance, and blood sugar level stabilization.

“Chronic viral infections like EBV significantly impact the body,” Mr. Galyardt notes, stressing the importance of overall health. “Keeping our body systems in optimal condition will help prevent and treat chronic viral loads better than any medication out there.”

Dr. Bauerschmidt takes a similar approach, focusing on the roots of immune dysfunction. He promotes oxygen therapy: “Oxygen is essential to eliminate the body’s toxin burden.” He compares traditional treatments like antibiotics and antivirals to using premium fuel without improving the engine—more expensive but not more effective.

At Deeper Healing, Dr. Bauerschmidt uses altitude contrast oxygen therapy, hyperbaric methods, and nighttime oxygen concentrators. He finds a combination of ozone therapy and ultraviolet blood radiation especially effective. For active viral infections, he has found nebulizing with high-quality colloidal silver or 0.3 percent hydrogen peroxide beneficial for some patients.

As research into EBV and the immune system progresses, it holds the promise of new management and treatment strategies for the virus’s associated conditions.

For individuals like Ms. Francis, this research offers hope and the promise of a more proactive approach to managing their health. As the medical community gains a deeper understanding of EBV’s interactions with the immune system, the potential for more targeted and effective treatments grows, bringing hope to millions affected by this pervasive virus.

A 70-Year-Old Woman with Cough and Shortness of Breath


Presentation of Case

Dr. Alison C. Castle: A 70-year-old woman with advanced human immunodeficiency virus (HIV) infection was evaluated in a clinic in KwaZulu-Natal, South Africa, because of cough, shortness of breath, and malaise.

Fifteen years before the current presentation, the patient received a diagnosis of HIV infection after she had presented with substantial weight loss and fatigue. The initial CD4 cell count obtained at the time of diagnosis was 29 cells per microliter (reference range, 332 to 1642). Antiretroviral therapy (ART) with stavudine, lamivudine, and efavirenz was started. During the subsequent year, the symptoms resolved, the HIV RNA level became undetectable, and the patient reported adherence to her medications. Ten years before the current presentation, additional ART became accessible within South Africa, and the ART regimen was changed to tenofovir disoproxil fumarate, emtricitabine, and efavirenz.

Five years before the current presentation, the patient was admitted to a local hospital because of diarrhea and diffuse myalgias, and she was found to have virologic failure. The ART regimen was changed to zidovudine, lamivudine, and lopinavir–ritonavir. During the subsequent 4 years, the patient reported adherence to these medications without a lapse in treatment. The HIV RNA level ranged from 68 to 594,000 copies per milliliter of plasma (reference value, undetectable).

Twelve months before the current presentation, the patient had new shortness of breath, cough, anorexia, and weight loss. During the subsequent 4 weeks, the symptoms progressively increased in severity. When the shortness of breath worsened to the extent that she was unable to walk, she sought evaluation at the clinic. The temporal temperature was 36.8°C, the blood pressure 104/64 mm Hg, and the pulse 87 beats per minute. The body-mass index (the weight in kilograms divided by the square of the height in meters) was 16.9. On examination, the patient appeared ill but was able to speak in full sentences. Auscultation of the chest was limited because of frequent coughing; diffuse crackles were present in both lungs.Table 1.Laboratory Data.

Nucleic acid testing of a nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Examination of an acid-fast bacilli smear of the sputum was positive for mycobacteria, and subsequent nucleic acid testing and culture of the sputum was positive for Mycobacterium tuberculosis. Other laboratory test results are shown in Table 1. In accordance with recommendations from the South African Department of Health, the patient was instructed to isolate at home and complete a course of treatment for tuberculosis, which included rifampin, isoniazid, pyrazinamide, and ethambutol.

During the subsequent 6 months, the patient took the antimycobacterial medications, and the shortness of breath and cough decreased but still persisted. Her weight decreased by 8 kg, even though the anorexia had resolved. Four months before the current presentation, new headaches and mouth ulcers developed, and the patient sought evaluation at the clinic. A sputum specimen was obtained for examination of an acid-fast bacilli smear and mycobacterial nucleic acid testing and culture, all of which were negative. The HIV RNA level was 151,000 copies per milliliter of plasma. The patient was scheduled for a follow-up appointment.

Twelve days before the current presentation, the patient presented to the clinic for follow-up, and the ART regimen was changed to tenofovir disoproxil fumarate, lamivudine, and dolutegravir. When the symptoms did not abate, the patient presented to the clinic for additional evaluation. She described persistent shortness of breath and dry cough, as well as headaches on the right side and mouth ulcers. The review of systems was notable for fatigue and weakness during the past 12 months, as well as fever, night sweats, chest pain, mouth ulcers, and odynophagia. She had no ageusia, anosmia, vision changes, abdominal pain, nausea, vomiting, diarrhea, rash, or joint pain. Radiography of the chest had not been performed.

The patient had not received vaccines for coronavirus disease 2019 (Covid-19). She took tenofovir disoproxil fumarate, lamivudine, and dolutegravir, as well as acetaminophen for muscle pain as needed. There were no known drug allergies. She did not smoke cigarettes, drink alcohol, or use illicit drugs; she did not take any remedies from traditional healers. The patient lived with her daughter in a rural farming community in a coastal region of South Africa, and she had not traveled recently. She commuted by foot within her community and had regular exposure to cattle, goats, chickens, and dogs. Her household water supply originated from a borehole and was untreated.

On examination, the patient was alert but appeared ill and cachectic. She coughed throughout the interview. The blood pressure was 97/71 mm Hg, the pulse 91 beats per minute, and the respiratory rate 20 breaths per minute. The body-mass index was 13.7. The mucous membranes were dry. She had thrush on the tongue, as well as superficial ulcers on the buccal mucosa. On auscultation of the chest, diffuse crackles were present in both lungs and were worst in the right lower lobe. The remainder of the physical examination was normal. The blood levels of alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were normal. Other laboratory test results are shown in Table 1.

A diagnostic test was performed.

Differential Diagnosis

Dr. Rajesh T. Gandhi: I am aware of the final diagnosis in this case. This 70-year-old South African woman, who had advanced HIV infection and a recent history of Covid-19 and pulmonary tuberculosis, presented with dyspnea, cough, odynophagia, and headaches. On examination, she had oral candidiasis, oral ulcers, and pulmonary crackles. Laboratory studies were notable for pancytopenia, a low CD4 cell count (<10 cells per microliter), and a decrease in the HIV RNA level after a recent viral rebound. Radiographs were not available.

When formulating a differential diagnosis, I will first define the features of her underlying condition, including her recent infections and immunocompromised state. Then, I will identify potential causes of her initial respiratory symptoms. Ultimately, I will refine the differential diagnosis on the basis of subsequent features of her presentation, including the oral ulcers and headaches.

DEFINING THE FEATURES OF THE PATIENT’S UNDERLYING CONDITION

At the time of the diagnosis of HIV infection, the patient had had a CD4 cell count of 29 cells per microliter — the diagnosis in this patient, as in many patients, was delayed until she already had a low CD4 cell count.1-3 A delayed diagnosis of HIV infection puts patients at risk for many opportunistic infections and cancers, puts sexual partners at risk for HIV acquisition, and is associated with a higher risk of subsequent complications, most likely because of a “legacy effect” of immune dysregulation.4 In addition to advanced HIV infection, the patient had a recent history of SARS-CoV-2 infection. Studies suggest that persons with HIV infection have worse Covid-19 outcomes, particularly if they have a low CD4 cell count or a high HIV RNA level.5-8 The patient’s markedly immunocompromised state placed her at risk for persistent SARS-CoV-2 infection and subsequent fungal superinfection. Finally, she had a recent history of pulmonary tuberculosis, which also increases the risk of severe Covid-19 outcomes and fungal superinfection, perhaps because of lung damage.5

IDENTIFYING POTENTIAL CAUSES OF THE PATIENT’S INITIAL RESPIRATORY SYMPTOMS

In this patient with advanced HIV infection, potential causes of her initial respiratory symptoms include noninfectious complications, such as cancer and heart failure, as well as infectious causes of pneumonia.

Cancer

Advanced HIV infection is associated with several cancers, including non-Hodgkin’s lymphoma and human herpesvirus 8–associated cancers, such as Kaposi’s sarcoma. Kaposi’s sarcoma can involve the lungs but is an unlikely diagnosis in this patient for two reasons. First, there were no evident mucocutaneous lesions, unless the oral ulcers were sarcomatous lesions. Second, Kaposi’s sarcoma is less common in women than in men who have sex with men, owing to a difference in the prevalence of human herpesvirus 8.

HIV Cardiomyopathy

Advanced HIV infection is associated with dilated cardiomyopathy and heart failure.9 However, this diagnosis would not explain other features of this patient’s clinical presentation, such as the oral ulcers and headaches.

Bacterial Pneumonia

Bacterial pneumonia occurs frequently in persons with HIV infection and may be due to one of several common or uncommon organisms, such as Streptococcus pneumoniaeHaemophilus influenzaeStaphylococcus aureusPseudomonas aeruginosaMycoplasma pneumoniae, or Chlamydia pneumoniae. This patient had been exposed to farm animals, which suggests the possibility of infection with rhodococcus species (after horse exposure) or C. psittaci (after exposure to pet birds or poultry). Exposure to goats and sheep suggests the possibility of infection with Coxiella burnetii, but the patient’s normal levels of alanine aminotransferase and aspartate aminotransferase make this diagnosis unlikely. Legionella can be found in borehole water, which she had ingested, but it is more common in manmade aquatic reservoirs.10 Nocardia may cause pneumonia and spread to the central nervous system; nocardiosis is a consideration, given her new headaches. However, this patient had had cough and dyspnea for several months, which makes most types of bacterial pneumonia unlikely because they tend to have a more acute presentation and progress over a shorter period of time.

Mycobacterial Pneumonia

Patients with M. tuberculosis infection and a low CD4 cell count can present with opacities in the middle or lower lobes, lymphadenopathy, and a miliary pattern on chest radiography. Drug-resistant M. tuberculosis infection would be a possibility if the patient had had incomplete adherence to her antimycobacterial medications. However, 4 months before the current presentation, follow-up mycobacterial nucleic acid testing of the sputum had been negative, which makes this diagnosis unlikely. M. avium complex usually causes disseminated infection, rather than pulmonary disease, in persons with advanced HIV infection.

Fungal Pneumonia

Pneumocystis jirovecii pneumonia is one of the most common opportunistic infections in persons with HIV infection. Patients with P. jirovecii pneumonia typically present with cough, dyspnea, fever, and hypoxemia, which is sometimes exertional. However, this diagnosis would not explain the patient’s oral ulcers or headaches.

Other potential fungal causes of pneumonia in persons in southern Africa with advanced HIV infection are Emergomyces africanus (formerly emmonsia species), cryptococcus, aspergillus, blastomyces, and histoplasma. E. africanus is the most common dimorphic fungus implicated in human disease in southern Africa and can cause pulmonary or disseminated infection in persons with HIV infection.11 Cryptococcal infection may lead to pneumonia and often results in meningitis, which could explain the headaches in this patient. However, a serum lateral flow assay for cryptococcal antigen was negative, which rules out cryptococcal meningitis, although not cryptococcal pneumonia. Aspergillus can cause pulmonary infection; risk factors for pulmonary aspergillosis in this patient include the low CD4 cell count, leukopenia, and recent history of Covid-19 and tuberculosis.

Parasitic Pneumonia

Potential parasitic causes of pneumonia in persons with advanced HIV infection include toxoplasma, strongyloides, cryptosporidium, and microsporidium. However, other features of this patient’s presentation, including the oral ulcers and headaches, would not be easily explained by infection with these parasites.

Viral Pneumonia

Influenza tends to be more severe in immunocompromised patients, including those with advanced HIV infection.12 Viral pneumonia can also be caused by respiratory syncytial virus, parainfluenza viruses, human metapneumovirus, cytomegalovirus (although rarely in persons with HIV infection), or SARS-CoV-2.

REFINING THE DIFFERENTIAL DIAGNOSIS

After the patient’s initial respiratory symptoms, odynophagia and mouth ulcers developed. In a patient with advanced HIV infection, potential causes of these symptoms include infection with aspergillus, histoplasma, candida, cytomegalovirus, herpes simplex virus, or SARS-CoV-2. Noninfectious possibilities include lymphoma and aphthous ulcers. Only some of these causes would also explain her respiratory symptoms, with aspergillus, histoplasma, and SARS-CoV-2 infections leading the list.

Headaches also developed late in this patient’s clinical course. Possible causes include a focal brain lesion (including brain abscess), bacterial or fungal sinusitis, and meningitis. Bacterial causes are somewhat less likely to be the sole explanation, given her protracted disease course. It is notable that fungal infections, including aspergillosis, have been reported to cause sinus disease and focal brain lesions in persons with advanced HIV infection.

Finally, is there an explanation for the progression of shortness of breath, cough, headache, and mouth ulcers after the initiation of effective ART? The patient’s worsening condition may be attributed to immune reconstitution inflammatory syndrome (IRIS). She had risk factors for IRIS: low CD4 cell counts, a high HIV RNA level, and the recent initiation of effective ART. Multiple opportunistic infections and cancers can worsen after the initiation of ART. A potential case of IRIS in the context of acquired immunodeficiency syndrome (AIDS) and Covid-19 has been reported.13

PUTTING IT ALL TOGETHER

How can we best explain this patient’s initial respiratory symptoms, followed by the development of odynophagia, mouth ulcers, and headaches? Given her markedly immunocompromised state, I am concerned about the possibility of persistent SARS-CoV-2 infection. Persistent SARS-CoV-2 infection has been reported in immunocompromised hosts, including those with advanced HIV infection.14 In several cases, other opportunistic conditions or superinfections were also present.

The persistence of SARS-CoV-2 infection in persons with advanced HIV infection may lead to the evolution of SARS-CoV-2 viral mutations. In an instructive report, a severely immunocompromised woman with HIV infection was positive for SARS-CoV-2 RNA for more than 210 days; during that time, the spike gene of the virus developed multiple mutations associated with immune evasion.15 The patient eventually cleared SARS-CoV-2 RNA after her HIV RNA level was suppressed with the use of ART.16 This case and others highlight the importance of identifying persons with HIV infection, treating them with ART, and prioritizing Covid-19 vaccination and treatment in this population.

In addition, persistent SARS-CoV-2 infection would place this patient at risk for a superinfection that might explain the new onset of headaches. Superinfections that can occur after Covid-19 include fungal infections, such as aspergillosis or mucormycosis, which can lead to pneumonia or rhino-orbital cerebral disease. The mechanisms that confer a predisposition to fungal superinfection in patients with Covid-19 are unclear, but such superinfection may in part be related to epithelial injury by SARS-CoV-2 leading to enhanced fungal binding to airways or impaired antifungal immunity from lymphopenia.17 This patient had additional risk factors for aspergillosis, including advanced HIV infection, leukopenia, and potential lung disease related to her recent tuberculosis.17-19

Given this patient’s profound immunodeficiency, I suspect that she has persistent SARS-CoV-2 infection, which may account for some aspects of her clinical presentation (fever, cough, dyspnea, and an abnormal lung examination). In the context of Covid-19 and a low CD4 cell count, pulmonary and cerebral aspergillus superinfection could be the cause of her respiratory symptoms and headaches. An additional evaluation, including SARS-CoV-2 testing as well as chest and head imaging, is warranted.

Dr. Rajesh T. Gandhi’s Diagnosis

Advanced human immunodeficiency virus infection, persistent severe acute respiratory syndrome coronavirus 2 infection, and pulmonary and cerebral aspergillus superinfection.

Diagnostic Testing

Figure 1.Results of RT-PCR Testing for SARS-CoV-2.

Dr. Tulio de Oliveira: A reverse-transcriptase polymerase-chain-reaction (RT-PCR) test of a nasopharyngeal specimen was positive for SARS-CoV-2. Two gene targets were detected (the N gene and ORF1ab targets), but the S gene target was not detected. The mean cycle threshold value was 18.3. Details of two additional positive SARS-CoV-2 RT-PCR tests were retrieved from laboratory records, the first from 11 months before presentation and the second from 3 months before presentation (Figure 1). No negative SARS-CoV-2 RT-PCR tests were documented between the positive tests.Figure 2.Phylogenetic Tree of SARS-CoV-2 Delta Sequences.

Repeated positive SARS-CoV-2 RT-PCR tests could reflect reinfections with different SARS-CoV-2 variants or persistent infection.20 Residual specimens from the current test and the test performed 3 months before presentation were retrieved for SARS-CoV-2 whole-genome sequencing; no stored specimen was available from the first test, performed 11 months before presentation. Results of phylogenetic analysis were consistent with persistent SARS-CoV-2 infection; both genomes were clustered together on a long branch within the delta clade (Figure 2).Figure 3.Mutations in the Spike Gene.

The genomes showed substantial evolution from the delta variant (B.1.617.2), with amino acid changes particularly concentrated in the spike gene. As compared with the sequence for the delta variant, the sequence from the patient 3 months before presentation had 14 additional mutations in the spike gene (13 substitutions and one deletion) (Figure 3). The sequence from the patient at the time of the current presentation showed 5 additional amino acid substitutions in the spike gene, as well as a new deletion in the N-terminal domain (67–79del) that was probably responsible for the S gene target failure. Furthermore, there was evidence of continued evolution at a key neutralizing antibody escape residue, from F486L to F486V. Taken together, the genomic data strongly pointed toward persistent SARS-CoV-2 infection with intrahost evolution.

Laboratory Diagnosis

Advanced human immunodeficiency virus infection and persistent severe acute respiratory syndrome coronavirus 2 infection.

Discussion of Management

Dr. Richard J. Lessells: Since late 2020, there have been multiple reports of persistent SARS-CoV-2 infection with intrahost evolution, usually in immunocompromised hosts. In South Africa, we have documented persistent infections in persons with advanced HIV infection.16,21 Suspected persistent infections can be identified from longitudinal follow-up of individual patients in clinical care or research studies, from active surveillance for suspected reinfections or persistent infections, or from targeted investigation of unusual sequences obtained during routine genomic surveillance.

There are no specific evidence-based management guidelines for persistent SARS-CoV-2 infection.22 Case reports of persistent infection have described treatment with antiviral agents, monoclonal antibodies, and convalescent plasma, often in combination, but the efficacy of any single or combination therapy for persistent infection has not yet been established.23,24 At the time of the patient’s current presentation, antiviral agents (remdesivir, molnupiravir, and nirmatrelvir–ritonavir) and monoclonal antibodies were either not yet approved or not available for use in the public health sector in South Africa. Anti–SARS-CoV-2 monoclonal antibodies are no longer active against circulating subvariants of the omicron variant (B.1.1.529).

Effective treatment of the underlying disease is an essential component of the management of persistent SARS-CoV-2 infection in immunocompromised patients. Limited evidence from case reports of persistent SARS-CoV-2 infection in patients with advanced HIV infection suggests that effective clearance of SARS-CoV-2 can occur after the commencement of effective ART and HIV suppression.16,21 Given the treatment history in this patient, the ART regimen was changed to a once-daily fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and dolutegravir just before the current presentation.

Follow-up

Dr. Nithendra Manickchund (Internal Medicine): Because no antiviral therapies for SARS-CoV-2 infection were available in South Africa at the time of the patient’s current presentation, the goal was to suppress HIV replication and reconstitute her immune system to resolve the Covid-19. Five weeks after the ART regimen was changed to a dolutegravir-based regimen, the patient began to have severe headaches on the right side, ptosis of the right eye, and an inability to move her right eye laterally. She presented to the clinic with these acute neurologic changes and was transferred to the hospital out of concern for IRIS. Computed tomography (CT) of the head, performed after the administration of intravenous contrast material, revealed a mass in the cavernous sinus with occlusion of the right internal carotid artery. Aspergillus fumigatus was isolated from two sputum specimens. On review of a second CT scan of the head, the mass was thought to be suggestive of aspergillosis, and treatment with intravenous amphotericin B was initiated.

RT-PCR testing of nasopharyngeal specimens for SARS-CoV-2 remained positive for the first 2 weeks of the hospitalization, but the infection had resolved by the third week. The patient neared HIV suppression at that time, with an HIV RNA level of 118 copies per milliliter of plasma, and had a modest improvement in the CD4 cell count. While awaiting biopsy for the intracranial mass, the patient died suddenly in the hospital. A postmortem examination was not performed.

Final Diagnosis

Advanced human immunodeficiency virus infection, persistent severe acute respiratory syndrome coronavirus 2 infection, and rhinocerebral aspergillus superinfection.

Watch “Gravitas: 64-yr-old becomes first woman to be cured of HIV” on YouTube


AIDS success ‘unworkable’ for vast majority


Graphic representation of the AIDS virus.

Graphic representation of the AIDS virus. Copyright: Preshkova,

Speed read

  • For the second time, a bone marrow transplant eliminates the AIDS virus from the blood of a patient
  • Given its complexity and cost, this method is not likely to be used on a large scale
  • Pending ongoing research, ARVs remain the recommended treatment
Medical experts hailed the news this week that a second HIV-positive man appears to have eliminated the virus from his body, but warned the treatment used is completely unviable for the vast majority of the 37 million people living with the disease.

AIDS, caused by infection with the human immunodeficiency virus (HIV) virus, is one of the three big diseases affecting people in the developing world along with tuberculosis and malaria. Around a million people died from AIDS-related illnesses in 2017.

Researchers from University College London (UCL) reported 5 March in the journal Nature the case of an HIV-positive man who, after receiving a bone marrow transplant, no longer showed any sign of the AIDS virus, 18 months after he had stopped taking antiretroviral therapy.

Presenting their work on the same day at the annual conference on retroviruses and opportunistic infections in Seattle, USA, the researchers said they used largely the same method which had been used in 2007 in Berlin on Timothy Ray Brown.

“Even reaching a very limited number of people to achieve ‘near-cure’ of HIV infection is a welcome achievement. It still seemed utopian a decade ago.”

Avelin Aghokeng

The so-called “Berlin patient” is considered the first person in the world to have been cured of HIV/AIDS, as the virus has not been detected in his body since then.
The method involves finding a compatible donor who additionally has a mutation in a gene called CCR5.
It is this gene that causes the AIDS virus to penetrate the immune cells and multiply. But the mutation prevents the virus from entering and taking hold.

As a stem cell, the transplanted bone marrow will produce new immune cells containing the mutated CCR5 gene which will gradually replace the old cells, blocking the virus, which can no longer replicate.

“Continuing our research, we need to understand if we could knock out this receptor in people with HIV, which may be possible with gene therapy,” said Ravindra Gupta, lead author of the study in a statement published by UCL.

There are strong reservations about this method, however, among parts of the scientific community.

Eric Delaporte, head of the laboratory for translational research on HIV and infectious diseases at the Institute of Research for Development (IRD), in France, says the rare genetic mutation is only found in one per cent of the population.

“As is often the case with AIDS, we are dealing with an overrepresentation of a result where we speak of ‘healing’, when in practice, for the millions of people living with HIV, this is not the solution,” he tells SciDev.Net.

‘False hope’

Delaporte also finds the process “complicated and dangerous”.

“You have to put the patient in aplasia, that is, destroy the cells with chemotherapy and then transplant the marrow of a compatible donor,” he says.

“During the aplasia phase when cells are destroyed, the slightest infection can kill, because the patient has no defence. It must therefore take place in a specialist unit with a sterile room, so with an advanced, sophisticated and expensive medical infrastructure.”
For Delaporte, the excitement around the story gives “false hope”.
But Michel Sidibé, executive director of UNAIDS, gives a more nuanced view.
“Although this breakthrough is complicated and much more work is needed, it gives us great hope for the future that we could potentially end AIDS with science, through a vaccine or a cure,” he wrote in a press release issued by the organisation.
“However, it also shows how far away we are from that point and of the absolute importance of continuing to focus HIV prevention and treatment efforts.

Sidibé’s optimism is shared by Avelin Aghokeng, researcher at the International Centre for Medical Research in Franceville, Gabon.

“Even reaching a very limited number of people to achieve ‘near-cure’ of HIV infection is a welcome achievement. It still seemed utopian a decade ago,” he says.
“Advances in research are enriched by such proofs of concept and open up new avenues for research and intervention.”

‘Proof of concept’

“Although it is not a viable large-scale strategy. these new findings reaffirm our belief that there exists a proof of concept that HIV is curable,” says Anton Pozniak, president of the International AIDS Society (ISA).

The British infectious disease specialist said he hoped “that this will eventually lead to a safe, cost-effective and easy strategy to achieve these results using gene technology or antibody techniques.

The authors of the work prefer to focus on the potential for the scientific community.

“If it is too early to say for sure that our patient is now cured of HIV, the apparent success of stem cells gives hope that new strategies can be developed to combat the disease,” says research team member Eduardo Olavarria.

Commenting on the findings in relation to the 2007 case, Aghokeng says the question of reproducibility of a procedure, experiment or intervention is “crucial””It is difficult,” he says, “to draw important conclusions from a single case. A second success, realized by another research team and in a different patient, allows scientists to confirm the first result and consider the experiment reproducible,” he tells SciDev.Net.

“It also helps to better control the approach, its benefits and also its limitations and dangers. It should be noted that behind this success are also many failures of this approach.”
Meanwhile, everyone in the scientific community agrees that the only way to treat this disease, which affects 37 million people worldwide, according to UNAIDS, is to take antiretrovirals for life.

How AIDS conquered North America: Researchers restore HIV genomes from serum samples more than 40 years old


HI
HIV particles (yellow) infecting a T cell, viewed under a scanning electron microscope. T-cells perform important functions in our immune system. 

Researchers at the University of Arizona and the University of Cambridge in the U.K. have reconstructed the origins of the AIDS pandemic in unprecedented detail.

The findings were made possible by a molecular technique the team developed for this project, enabling them to recover genetic material from more than 40-year-old serum samples and decipher the gene sequence of the , or HIV, subtype that started the outbreak on the North American continent in the early 1970s. Phylogenetic analyses estimate the jump to the U.S. at about 1970 and place the ancestral U.S. virus in New York City, strongly suggesting this was the crucial hub from which HIV made its way across the continent.

Insights gained from this study may help researchers and health officials better understand how pathogens move through populations and lead to more effective strategies aimed at reining in, or eradicating, dangerous pathogens.

The results will be published in the advance online publication of Nature on Oct. 26. They confirm previous findings retracing the routes by which the virus entered and spread through the U.S. and eliminate any remaining doubt surrounding the Caribbean region as a key steppingstone from which HIV jumped into the U.S. The paper also reports the first recovery of the full HIV-1 genome from an individual known as “Patient Zero” and shows that there is neither biological nor historical evidence for the widely held belief that he was the primary cause of the HIV epidemic in North America.

While it had been established that HIV already was infecting people in the U.S. before 1981, the year AIDS was recognized, the timing and earliest movements of the virus in the U.S. were unknown until now. Leading an interdisciplinary team of scientists, Michael Worobey, an expert on , and Richard McKay, a scholar specializing in the history of public health, set out on a quest to unravel the secrets surrounding the AIDS epidemic as it unfolded. The endeavor called for new molecular techniques that would make it possible to recover and “restore” genetic material from samples whose age and condition made them intractable to existing analytic methods.

The findings were made possible by a molecular technique the team developed for this project, enabling them to recover genetic material from more than 40-year-old serum samples and decipher the gene sequence of the , or HIV, subtype that started the outbreak on the North American continent in the early 1970s. Phylogenetic analyses estimate the jump to the U.S. at about 1970 and place the ancestral U.S. virus in New York City, strongly suggesting this was the crucial hub from which HIV made its way across the continent.

Insights gained from this study may help researchers and health officials better understand how pathogens move through populations and lead to more effective strategies aimed at reining in, or eradicating, dangerous pathogens.

The results will be published in the advance online publication of Nature on Oct. 26. They confirm previous findings retracing the routes by which the virus entered and spread through the U.S. and eliminate any remaining doubt surrounding the Caribbean region as a key steppingstone from which HIV jumped into the U.S. The paper also reports the first recovery of the full HIV-1 genome from an individual known as “Patient Zero” and shows that there is neither biological nor historical evidence for the widely held belief that he was the primary cause of the HIV epidemic in North America.

While it had been established that HIV already was infecting people in the U.S. before 1981, the year AIDS was recognized, the timing and earliest movements of the virus in the U.S. were unknown until now. Leading an interdisciplinary team of scientists, Michael Worobey, an expert on , and Richard McKay, a scholar specializing in the history of public health, set out on a quest to unravel the secrets surrounding the AIDS epidemic as it unfolded. The endeavor called for new molecular techniques that would make it possible to recover and “restore” genetic material from samples whose age and condition made them intractable to existing analytic methods.

“Standard methodology such as antibody-detecting serological blood tests will tell you whether a person had HIV, but you might not be able to get any of the HIV gene sequences out of it, because to do that, you need the RNA from the virus,” says Worobey, a professor and head of the UA’s Department of Ecology and Evolutionary Biology. “The virus’ RNA is an extremely delicate molecule comprising 10,000 nucleotides, and breaks down very quickly.”

Worobey’s lab developed a technique called RNA jackhammering, which breaks down the huge human genome in the samples into tiny overlapping chunks and extracts the RNA of the virus.

“We then very carefully amplify the RNA of the virus without letting the background RNA get in the way,” he explains.

Worobey says the technique may hold potential for other health care applications, such as more sensitive bioassays for screening blood samples for cancer markers or viruses, including Zika.

How AIDS conquered North America
After HIV moved from Africa to the Caribbean, it first spread to New York and subsequently to different locations in the U.S. By constructing evolutionary trees of the various HIV strains as far back as the 1970s, the researchers found evidence that the virus had been circulating under the radar for ten years before the outbreak in the US was recognized. 

By screening more than 2,000 serum samples collected from U.S. men between 1978 and 1979, all of which degraded over time, the technique allowed the researchers to recover eight near full-length viral RNA genome sequences, representing the oldest HIV genomes in North America. This early, full-genome “snapshot” reveals the U.S. HIV-1 epidemic showed surprisingly extensive genetic diversity in the 1970s but also provides strong evidence of its emergence from a pre-exiting Caribbean epidemic.

Having the complete genomic information in front of them allowed the authors to tackle questions that had vexed researchers—for example, how quickly the virus was spreading at different times in different locations. Once HIV had crossed the Atlantic from Africa, it quickly spread through the Caribbean and from there into the U.S. Yet, the epidemic went unnoticed until it hit the U.S. New York City turned out to be the most critical hub for the AIDS epidemic in the U.S., and the newly sequenced genomes showed the virus must have jumped there in, or very near, 1970. From there, HIV spread to San Francisco and presumably to other locations in California, where AIDS patients were first recognized in 1981.

“In New York City, the virus encountered a population that was like dry tinder,” Worobey explains, “causing the epidemic to burn hotter and faster and infecting enough people that it grabs the world’s attention for the first time.

“That information is stamped into the RNA of the virus from 1970,” he says. “Our analysis shows that the outbreaks in California that first caused people to ring the alarm bells and led to the discovery of AIDS were really just offshoots of the earlier outbreak that we see in New York City.”

From the genetic data, the team was able to construct evolutionary trees of the various HIV strains and how they spread through the U.S. They revealed that by the late 1970s HIV had diversified in almost the same genetic diversity we see today.

“Right around 1970, we see the signal of emergence of this virus, which is evidence that it had to have been there at that point in time in at least one person,” Worobey says.

Being able to look back in time and piece together what it took for the HIV pandemic to happen is encouraging, the researchers say.

“Now we can now look forward in time and really see a future in which—even if the virus is not completely eliminated—it could be driven down to no new transmission in large swaths of the world,” Worobey says.

The molecular biology assays developed in this work could lead to more sensitive tests that detect the virus sooner in people who are unaware that they were infected very recently, he says.

“Earlier detection and better alignment of the various options we have to make it harder for the to move from one person to the next,” he says, “are key to driving HIV out of business.”

GENE THERAPY UPDATE: POTENT WEAPONS AGAINST AIDS, CANCER AND MORE


Hard to believe it was once considered little more than theory. Or the stuff of science fiction.

In the past year, leading-edge gene therapy – the process of fighting lethal illnesses by manipulating their mechanisms at the cellular level – has continued to take bold steps out of the laboratory and into the realm of potentially lifesaving treatments. It is no longer beyond imagination, or even far-fetched, to envision a day when, thanks to edited genes, advanced brain tumors disappear, hemophiliacs create their own clotting factor and AIDS patients can stop taking their daily antiviral drugs.
“The field of cell-based therapy is becoming more mature,” says John Zaia, M.D., the Aaron D. Miller and Edith Miller Chair in Gene Therapy, and director of City of Hope’s Center for Gene Therapy.
In typical City of Hope style, theoretical science is getting down to business, with multiple clinical trials underway at City of Hope’s now one-year-old Alpha Clinic. Patients are being recruited to test the safety of gene-based treatments for several cancers, as well as hemophilia and HIV/AIDS.
Leader in HIV/AIDS Research
Zaia, who’s devoted much of his professional life to the AIDS battle, is especially excited about two unique stem cell transplant options that target HIV in different ways. One employs a zinc finger nuclease, or ZFN, to “edit out” the CCR5 receptor on a patient’s harvested stem cells, then reintroduce them. The modified cells deny HIV its normal path to infection.
Another approach uses a lentivirus to add re-engineered, anti-HIV ribonucleic acid (RNA) genes to stem cells, including one that disrupts CCR5.
In targeting CCR5, Zaia and his research colleagues around the world are trying to replicate the case of the so-called “Berlin patient” whose HIV vanished after he received a stem cell transplant for treatment of leukemia. The donor’s CCR5 gene had a mutation that blocked the virus. “There aren’t enough donors with that mutation to replicate the treatment on a large scale,” says Zaia, “so we have to artificially create the mutation.”
In March of 2016 the first patient received Zaia’s RNA/lentivirus-based treatment under an Food and Drug Administration-approved trial, which permits only one participant at a time. Four months later the recipient is tolerating the treatment well, and the accumulated data is providing critical information.
Clinical Trials’ Challenges
Finding the right patients for these trials is a special challenge. However, although the FDA now allows otherwise healthy people with HIV to participate, the risks associated with a stem cell transplant are high, because the patient must first receive an extremely potent course of chemotherapy to “create a space” for the transplanted cells. For this reason, the RNA/lentivirus trial is focused on AIDS patients with lymphoma who’ve completed treatment and are in remission.
“Those patients are just a better population for this trial,” says Zaia. “They’re also more likely to accept the risks.” He praises those willing to come forward, lauding their “wonderful and generous humanitarian gesture.”
As encouraging as the early results may be, they are baby steps. Current therapies modify only a relatively small percentage of a patient’s stem cells. Zaia hopes to one day develop a more efficient mechanism which would fortify a much larger percentage of stem cells, while protecting them from chemo’s toxic effects.
One possibility may emerge from the treatment of brain tumors performed by collaborators at the Fred Hutchinson Cancer Research Center. The usual chemotherapy drug of choice, BCNU, can be seriously toxic to bone marrow. When researchers altered a gene known as MGMT, the BCNU chemo worked more effectively and the marrow was protected.
It remains to be seen whether this approach would provide similar protection in HIV patients. The possibility is intriguing, and it’s one of many reasons Zaia stands by his prediction of a year ago that a “functional cure” for HIV/AIDS (in which the virus is effectively blocked and daily drugs are no longer needed) may be just five years away.
Making Inroads
In the meantime, gene-based technology is making inroads in other Alpha Clinic trials.
For example, the ZFN technique is being adapted for the treatment of hemophilia in which there is a lack of clotting factor. Using the same gene-editing mechanism, researchers have been able to “cut” a normal “housekeeping” gene  and introduce a “corrected” version of the clotting factor into the liver. The process has worked in animal tests, and human trials will begin soon.
Newer gene-editing methods are emerging as well, including the much-talked-about “CRISPR” technology which can find, cut out and replace specific parts of DNA using a specially-programmed enzyme. China is preparing to test CRISPR in the world’s first human trials, and the FDA has approved trials in the U.S., beginning probably next year. Zaia advises caution:
“We do not have clinical trials going for CRISPR-type treatment just ye. It’s much too new and we need to learn more about it. Bear in mind that it took nearly 15 years to get ZFN approved for human patients. But this could eventually be a game-changer, helping us direct our gene-editing efforts with much greater precision.”
The major partner in City of Hope’s gene therapy journey continues to be California’s stem cell agency, the Institute for Regenerative Medicine. CIRM grants helped establish the Alpha Clinic and other facilities across the state, and CIRM funding is fueling many of the ongoing clinical trials, including Zaia’s.
“California is ahead of the curve,” he says, “changing the culture of gene therapy.”

AIDS: 21st century’s biggest fraud.


http://www.pravdareport.com/health/16-05-2012/121133-aids_fraud-0/

AIDS: 21st Century’s biggest fraud. 47117.jpeg

Prince ‘diagnosed with AIDS weeks before his death and was preparing to die’ – shock US claims


Music icon Prince was “preparing to die for a little while” after being diagnosed with AIDS, according to reports in the US.

A music industry source interviewed by The National Enquirer messaged friends on April 19 to say the singer was suffering from the disease.

“He was in bad shape,” the source claimed to the newspaper, as reported by Radar Online.

“Doctors told Prince his blood count was unusually low and that his body temperature had dropped dangerously below the normal 98.6 degrees to 94 degrees.

“He was totally iron-deficient, very weak and often disoriented.

Musician Prince performs onstage at the 36th Annual NAACP Image Awards
Prince died last week

“He rarely ate and when he did, it all came right back up.”

The magazine claims the Purple Rain star was diagnosed with AIDS six months ago after contracting the HIV positive virus “in the 1990s”.

However due to his Jehovah’s Witness faith he refused medical treatment instead believing he could be cured by pray.

National Enquirer front page
Shock National Enquirer front page this week

“God can and will cure me,” he is alleged to have told friends.

Members of his faith are also claimed to have told him to ignore it, saying to the singer he had “everlasting life”.

According to the Enquirer the disease saw him lose more than five stone in weight with the source telling them: “His face was yellowish, the skin on his neck was hanging off and the tips of fingers were a brownish-yellow.”

Prince pictured in 2010

Days before he was dead in a lift at his Paisley Park home in Chanhassen, Minneapolis, he had been seen making runs to a local pharmacy to pick up bags of prescriptions.

An employee at the Walgreens that served Prince said: “We were all just shocked that he came in last night looking so beat. We said, ‘We are praying for you.’”

Prince leaving a Walgreens near his home in Minnesota Wednesday night (20th April) at around 7 PM
Prince leaving a Walgreens near his home

 

A day after his death Prince, 57, was cremated in a private ceremony attended by only three family members including his sister Tyka Nelson, 55.

The claims of Prince suffering from AIDS came as the Mirror learnt he was forced to return to touring in order to boost his finances after it was discovered his spending outstripped his income.

Despite his work being valued at more than £150 million he is said to have suffered “chronic money problems” for years before his death.

The star’s refusal to allow the rights to music and back catalogue to be sold placed an immense strain on his finances, sources close the singer have claimed.

Prince’s final words to his lawyer before he died at home in Minnesota
Tributes have been pouring in

Before his death the singer “consistently shut down” opportunities to fuel his finances, such as licensing his songs to be used in movies, TV shows and commercials.

A source said: “He refused to part with his art.

“He always remained true to his beliefs that his work was his own and despite lucrative offers his music was not for sale.

“To get much needed cash Prince braved the pain barrier to tour Australia earlier this year.

Prince has been remembered all over the world

“You can imagine the toll a 36 hour flight would take on his body.

“Although a genius of music, he was not a genius when it came to business.”

Sources close to the star point to how his frequent impulsive shows were poorly planned and involved little promotion, meaning that while some were successful, a lot were staged at a loss.

It had been reported that Prince’s estate was worth in the region of £200 but the figure is said to have been grossly exaggerated.

The rights to his music however have been estimated to be worth upwards of £150 million in the future.

Days before Prince’s death, two American websites posted a story about “a VERY popular African American celebrity” suffering from AIDS who they refused to name.

A skywritting tribute to Prince at the 2016 New Orleans Jazz & Heritage Festival
A tribute to Prince

On April 18 Blind Gossip posted: “We just received word that a VERY popular African American celebrity – who has recently been in the news – now has what is being described as AIDS.

“Obviously since we are not able to 100% confirm the story – we’re going to leave it as a Blind Item. We want to make it clear we are NOT talking about Magic Johnson.

“This report really hurt our heart.

“According to a person extremely close to the situation, the celebrity, who is known for having a very extreme sexual past reportedly contracted the illness sometime in the 1990s.

“He kept the illness quiet but began taking his medication religiously up until about 2 years ago.”

They finished the article saying: “We’re told that the celebrity is expected to get sicker and sicker, and eventually pass. It can happen as soon as the summer.

“Very sad news.”